Dr. Siegall of the Seatle Genetics Releases New Treatment

Dr. Siegall who co-founded the Seattle Genetics is the presiding Chief Executive Officer and the current president of the same company. The Seatle Genetics was founded in the year 1998 and under the leadership of Dr. Siegall the company has come up with chains of cancer therapies based on the antibody. ADCETRIS (brentuximab vedotin) is among the therapies that Seattle Genetics built and has gained accelerated approval by the Food and Drug Administration FDA in the SU since 2011.

Dr. Siegall has conducted fundraising activities for the company securing an amount reaching $675 million from the public and private sectors and the company’s initial offering. Dr. Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute up to 1997, National Cancer Institute and National Institute of Health till 1991. Dr. Siegall is also in the Aider Biopharmaceuticals a private biotechnology company, working as a member of the board of directors. Besides his career, he is an author of many publications and in addition to it holds 15 patents. Dr. Siegall holds a bachelors degree in zoology and a Ph.D. in genetics from the George Washington University of Maryland.

The Seattle Genetics has a recent ongoing research and has presented information at the AACR Annual Meeting on immunogenic cell death. The research incorporates two clinical trials and also involves the collaboration with nivolumab. Seatle Genetics collaborates with the Bristol Myers Squibb in the research. The development of the combined modalities speaks of the future treatment to be applied in oncology, and Seattle Genetics is a proud member of it.

Dr. Siegall expresses his pride in the recent product pipelines that are two in total: SGN-CD33A and SGN-CD19A. SGN-CD33A is a newly developed treatment that is focused on targeting the CD33 antibody that is usually found in all types myeloid leukemia cell. Targeted at treating acute myeloid leukemia.SGN-CD19A ADC targets the CD19 that is expressed in B-cell malignancies. SGN-CD19A is made up of an antibody that is linked a cell-killing agent. It is designed to be neutral when in the bloodstream and when it reaches the CD19A expressing tumors, it releases the cytotoxics.